View in EDS

An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin.

Saved in:
Bibliographic Details
Title: An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin.
Authors: Sneed SL; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, and., Reese BB; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, and., Laureano AF; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, and., Ratnapriya S; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, and., Fraschilla I; Center for the Study of Inflammatory Bowel Disease, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Jeffrey KL; Center for the Study of Inflammatory Bowel Disease, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Coffey GP; Nuvig Therapeutics, Redwood City, California, USA., Conley PB; Nuvig Therapeutics, Redwood City, California, USA., Anthony RM; Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, and.
Source: The Journal of clinical investigation [J Clin Invest] 2024 Feb 15; Vol. 134 (4). Date of Electronic Publication: 2024 Feb 15.
Publication Type: Journal Article
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI172980